Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

and VX-264, which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation of islet cells alone, using immunosuppression ...

Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

Vertex Pharmaceuticals is throwing in the towel on its investigational type 1 diabetes islet cell-device combination VX-264 after it failed to increase C-peptide in a 90-day study. Combination ...